Gathuru John K, Koide Fusataka, Ragupathi Govind, Adams Janet L, Kerns Robnet T, Coleman Timothy P, Livingston Philip O
Laboratory of Tumor Vaccinology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA.
Vaccine. 2005 Sep 15;23(39):4727-33. doi: 10.1016/j.vaccine.2005.05.007.
MUC1 is expressed at the cell surface of epithelial cancers. We have shown previously that MUC1 conjugated to keyhole limpet hemocyanin (KLH) plus the saponin immunological adjuvant QS-21 induces consistent high titer IgM and IgG antibodies in patients after treatment of their primary or metastatic cancers. KLH however is poorly soluble and heterogeneous making it difficult to work with, and we hypothesize that changing carrier proteins mid-way through a vaccination schedule would further increase antibody titers. Consequently, there is need for an alternative potent carrier protein. Duck Hepatitis B core antigen (DHBcAg) has a molecular weight of approximately 25kDa and is easily purified as a single band, but it self aggregates into particles of approximately 6.4x10(6)Da. Consequently, it is highly immunogenic, easy to work with and amenable to chemical and genetic conjugation to antigens such as MUC1. We compare here in mice the immunogenicity of MUC1 chemically conjugated to KLH or DHBcAg and MUC1-DHBcAg recombinant protein after an initial series of three vaccinations and then after an additional series of three vaccinations with the same or opposite carrier, all mixed with the saponin immunological adjuvant GPI-0100. High titer IgG antibodies were observed in all groups after the initial three vaccinations: MUC1-DHBcAg median ELISA titer 1/51200, RecMUC1-DHBcAg 1/25600 and MUC1-KLH 1/12800. This increased to 1/6553600 after the second set of three immunizations when the carrier remained the same in all three groups, but titers were significantly lower when the carriers were changed for the final three immunizations. These data demonstrate that DHBcAg is an excellent carrier protein and that changing carrier proteins does not further augment immunogenicity.
黏蛋白1(MUC1)在上皮癌的细胞表面表达。我们之前已经表明,与钥孔戚血蓝蛋白(KLH)结合并添加皂苷免疫佐剂QS-21的MUC1,在治疗原发性或转移性癌症的患者后可诱导产生持续的高滴度IgM和IgG抗体。然而,KLH溶解性差且不均一,难以进行操作,我们推测在疫苗接种计划中途更换载体蛋白会进一步提高抗体滴度。因此,需要一种替代的高效载体蛋白。鸭乙型肝炎核心抗原(DHBcAg)分子量约为25kDa,易于纯化得到单一条带,但它会自我聚集成约6.4x10(6)Da的颗粒。因此,它具有高度免疫原性,易于操作,并且适合与MUC1等抗原进行化学和基因偶联。我们在此比较了在小鼠中,MUC1与KLH或DHBcAg化学偶联以及MUC1-DHBcAg重组蛋白在最初的三次疫苗接种系列后,以及随后用相同或相反载体进行的另外三次疫苗接种系列后的免疫原性,所有疫苗均与皂苷免疫佐剂GPI-0100混合。在最初的三次疫苗接种后,所有组均观察到高滴度的IgG抗体:MUC1-DHBcAg的ELISA滴度中位数为1/51200,重组MUC1-DHBcAg为1/25600,MUC1-KLH为1/12800。当所有三组在第二组的三次免疫接种中载体保持相同时,滴度增加到1/6553600,但在最后三次免疫接种中更换载体时,滴度显著降低。这些数据表明,DHBcAg是一种优秀的载体蛋白,并且更换载体蛋白不会进一步增强免疫原性。